SCHEMBL2073052

SCHEMBL2073052

CC1(C)OB(c2ccc(NS(=O)(=O)c3ccccc3)c(-c3ccccc3)c2)OC1(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPL P06858 2/20 0.48
LIPG Q9Y5X9 2/20 0.48
CA2 P00918 4/20 0.47
CA9 Q16790 4/20 0.47
MCOLN3 Q8TDD5 3/20 0.47
LMNA P02545 3/20 0.47
CA12 O43570 2/20 0.47
ALDH1A1 P00352 5/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
CA1 P00915 3/20 0.42
CA3 P07451 1/20 0.42
CA4 P22748 1/20 0.42
CA6 P23280 1/20 0.42
CA5A P35218 1/20 0.42
CA7 P43166 1/20 0.42
CA14 Q9ULX7 1/20 0.42
CA5B Q9Y2D0 1/20 0.42
PDGFRB P09619 1/20 0.42
KDR P35968 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2074312 0.84 CRHBP (0.53) LPLLIPGCA2CA9CA12
SCHEMBL3638446 0.81 HSD17B10 (0.45) LPLLIPGCA2CA9CA12
SCHEMBL1331630 0.78 CA1 (0.64) LPLLIPGCA2CA9CA12
SCHEMBL11894843 0.77 HTR6 (0.51) CA2CA9LMNACA12ALDH1A1
SCHEMBL19533269 0.75 LIPG (0.66) LPLLIPGCA2CA9CA12
SCHEMBL29653625 0.75 LIPG (0.66) LPLLIPGCA2CA9CA12
SCHEMBL20995717 0.75 CA9 (0.62) LPLLIPGCA2CA9CA12
SCHEMBL9955288 0.75 PIK3CG (0.52) ALDH1A1PDGFRBKDRSMN1; SMN2PIK3CD
SCHEMBL28407595 0.74 LMNA (0.70) CA2CA9MCOLN3LMNACA12
SCHEMBL15091833 0.74 CA1 (0.49) LPLLIPGCA2CA9LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7863444-B2 4-aminopyrrolopyrimidines as kinase inhibitors ABBOTT LABORATORIES (US) 2011-01-04 US disclosed
EP-1114052-B1 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS ABBOTT GMBH & CO KG (DE) 2005-11-16 EP disclosed
US-20030187001-A1 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2003-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187001-A1 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS LCK, PPP5C, DUSP1 LPL 4053/4885LIPG 1486/4885CA2 3294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.